Pfizer will release its fourth-quarter earnings next month, and analysts anticipate a low double-digit profit dip.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

Let’s dive into details regarding each of the evaluated factors, but first, for quick context: With $143 Bil in market ...

Dividend stocks can be a good strategy for investors seeking a reliable and potentially more predictable stream of passive ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Pfizer enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution. Click here to read ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Pfizer has beaten its earnings per share (EPS) estimates in its past 12 quarters. Beating EPS estimates hasn't always meant positive movements for Pfizer's share price. The stock's low valuation and ...

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock. The company did show signs of progress in its ...

Pfizer is in the final stages of a deal to purchase Metsera, offering $47.50 in cash per share and an additional $22.50 if specific performance targets are achieved, as reported by Financial Times.

Shares of Pfizer Inc. PFE advanced 1.03% to $25.43 Tuesday, on what proved to be an all-around favorable trading session for ...